AIDA interactive educational freeware diabetes simulator

Last updated

AIDA is a freeware computer program that permits the interactive simulation of plasma insulin and blood glucose profiles for demonstration, teaching, self-learning, and research purposes. [1] Originally developed in 1991, [2] it has been updated and enhanced since, and made available without charge from 1996 on the World Wide Web. [3] The program, which is still being updated, has gone through a number of revisions and developments in the 16+ years since its original internet launch. Further copies of the simulator have been made available, in the past, on diskette by the system developers [4] [5] [6] and from the British Diabetic Association (BDA) — now called 'Diabetes UK' — London, England, [7] following the BDA's own independent evaluation of the software. [8] More than 1,075,000 diabetes simulations have been run via a web-based version of the AIDA diabetes simulator.

Contents

The AIDA software is intended to serve as an educational support tool and can be used by anyone — person with diabetes, relative of a patient, health care professional (doctor, nurse, clinical diabetes educator, dietician, pharmacist, etc.), or student — even if they may have minimal knowledge of the pathophysiology of diabetes mellitus.

Simulation from AIDA downloadable freeware diabetes simulator showing the effect of omitting a morning insulin injection (before breakfast at 8am). This would send the simulated virtual person with diabetes ('Joy Wilson' [pseudonym]) markedly hyperglycemic in the afternoon (with a predicted blood glucose level of 18.8 mmol/L [338 mg/dL] at 2:30pm) -- and leave her at significant risk of developing diabetic ketoacidosis. The simulated blood glucose profile is shown in the upper graph, and the carbohydrate intake and insulin injections are shown in the lower graph, with the simulated plasma insulin profile shown superimposed on the lower graph. The missed usual insulin injection is shown highlighted in yellow. Aida-h.gif
Simulation from AIDA downloadable freeware diabetes simulator showing the effect of omitting a morning insulin injection (before breakfast at 8am). This would send the simulated virtual person with diabetes ('Joy Wilson' [pseudonym]) markedly hyperglycemic in the afternoon (with a predicted blood glucose level of 18.8 mmol/L [338 mg/dL] at 2:30pm) — and leave her at significant risk of developing diabetic ketoacidosis. The simulated blood glucose profile is shown in the upper graph, and the carbohydrate intake and insulin injections are shown in the lower graph, with the simulated plasma insulin profile shown superimposed on the lower graph. The missed usual insulin injection is shown highlighted in yellow.

Overview of AIDA physiological model

AIDA has been described in detail in the medical / scientific / computing / diabetes literature. [9] It incorporates a compartmental model that describes glucose-insulin interaction in people completely lacking endogenous insulin secretion — i.e. insulin-dependent patients with type 1 diabetes mellitus. The AIDA model contains a single extra-cellular glucose compartment into which glucose enters via both absorption from the intestine and glucose production from the liver. The model also contains separate compartments for plasma and 'active' insulin, the latter being responsible for glycemic control while insulin is removed from the former by liver degradation. Full details of the AIDA model are accessible from within the AIDA software package, [10] and can be viewed and printed separately via the AIDA website.

Schematic summarising the anatomical basis and physiological functions of the AIDA model. Different glucose fluxes corresponding to the numbers (1 to 4) in this figure are shown. (1) glucose absorption from the gut; (2) insulin-independent glucose utilisation in the brain (central nervous system) and red blood cells; and insulin-dependent glucose utilisation in muscle and adipose tissue; (3) net hepatic glucose balance (production or utilisation of glucose by the liver); (4) renal excretion of glucose. Abbreviations: G.A.R.=glucose absorption rate (mmol/hr); N.H.G.B.=net hepatic glucose balance (mmol/hr/kg); I.I.G.U.=insulin independent glucose uptake (mmol/hr/kg); A.G.=arterial plasma glucose (mmol/L); P.G.U.=peripheral glucose uptake (mmol/hr/kg); B.G.=blood glucose (mmol/L); U.G.E.R.=urinary glucose excretion rate (mmol/hr); insulin (mU/L); time (hrs). AIDA-model.jpg
Schematic summarising the anatomical basis and physiological functions of the AIDA model. Different glucose fluxes corresponding to the numbers (1 to 4) in this figure are shown. (1) glucose absorption from the gut; (2) insulin-independent glucose utilisation in the brain (central nervous system) and red blood cells; and insulin-dependent glucose utilisation in muscle and adipose tissue; (3) net hepatic glucose balance (production or utilisation of glucose by the liver); (4) renal excretion of glucose. Abbreviations: G.A.R.=glucose absorption rate (mmol/hr); N.H.G.B.=net hepatic glucose balance (mmol/hr/kg); I.I.G.U.=insulin independent glucose uptake (mmol/hr/kg); A.G.=arterial plasma glucose (mmol/L); P.G.U.=peripheral glucose uptake (mmol/hr/kg); B.G.=blood glucose (mmol/L); U.G.E.R.=urinary glucose excretion rate (mmol/hr); insulin (mU/L); time (hrs).

Limitations of model

It is important to note that AIDA, like other model-based approaches, is not sufficiently accurate to be used for individual patient simulation or glycemic prediction. [11] [12] Therefore, as the program makes clear, it is not intended for insulin therapy planning and can only be used for teaching, self-learning, demonstration, or research purposes. While the AIDA software can simulate a wide variety of insulin dosage and diet (nutrition) adjustments, it should be stressed that the purpose of AIDA is to create a learning environment for communicating and training intuitive thinking when dealing with such adjustments. In this respect AIDA appears most of use for recreating clinical situations in diabetes care — rather than trying to predict best outcome.

Downloadable & on-line versions

The AIDA diabetes simulator comes in two forms.

Use as an educational tool

The AIDA software comes with forty educational case scenarios as standard, each of which represents a 'snapshot' of the metabolic status of a typical person with respect to insulin-dependent type 1 diabetes mellitus. It is easy for users to add or create further case scenarios, as required. Examples of the application of AIDA as an educational tool can be found in various published journal articles. [14] [15]

Simulating glycated hemoglobin (HbA1c) levels

Glycated hemoglobin (HbA1c) levels are widely regarded as a marker of medium-term blood glucose control and are extensively applied clinically as an indicator of a person's average or integrated glycemic control over the preceding 2–3 months. Diabetologists, endocrinologists, diabetes specialist nurses and diabetes educators use assessments of HbA1c levels to confirm overall blood glucose control; this test having the advantage of not being dependent on patient self-reported blood glucose data.

Since the year 2000, an estimate or simulation of HbA1c levels has been incorporated within the AIDA program. [16] This offers people with diabetes, their relatives, students, health-care professionals and other users an indication of what the HbA1c level might be if the simulated blood glucose profile was maintained for 2–3 months. The AIDA developers stress that such HbA1c level estimations, like AIDA's main blood glucose simulations, are only intended for educational / teaching, self-learning or demonstration purposes, and not meant for individual patient prediction or therapy planning. [17]

Teaching using simulator

User comments about AIDA have highlighted some of the many ways in which people have applied the simulations in their own particular situations. [18] A great deal of attention has focused, understandably, on use by individuals with diabetes and their relatives, as well as by health-care professionals such as diabetologists / endocrinologists and diabetes educators. However, an important group of health-carers involved in the provision of day-today care for many people with diabetes are primary care physicians (general practitioners [GPs]). A workshop was held in September 2000 in Italy — by an independent diabetologist / endocrinologist unconnected with the AIDA simulator's development — to gain experience with application of the AIDA diabetes simulation approach as a teaching tool for general practitioners (GPs). Feedback obtained from participants attending the workshop was very positive, with GPs reporting the simulation approach to be both of interest and use. [19]

Another important group of health-carers involved in the provision of day-to-day care for many people with diabetes are nurses. A separate workshop was held in June 2001 in Italy — by the same independent diabetologist / endocrinologist — to gain experience with application of the AIDA diabetes simulation approach as a teaching tool for student nurses. Feedback obtained from participants attending the workshop was generally very positive, with the student nurses also reporting the simulation approach to be both of interest and of use. [20]

High-school student teaching with AIDA on-line

The lifetime risk of developing diabetes for students born since the year 2000 in the United States is estimated to be 27% to 52%. [21] Many students need to learn about diabetes for their personal care, or for the care of relatives, or desire to learn about diabetes to develop a career in healthcare. Most teenagers are adept at learning through web-based computer tools. Against this background, 21 students entering the 8th and 9th grades (aged 12 to 14 years old) enrolled in a Biotechnology Summer Camp in June 2006 — organized independently by the Georgia Institute of Technology in Atlanta, Georgia (USA) — focusing on diabetes mellitus. Lectures on pathophysiology and clinical aspects of diabetes were followed by simulated cases using the AIDA on-line diabetes software simulator. Two cases demonstrated glycemic effects and pharmacokinetics of insulin administration, diet, and exercise in insulin-dependent type 1 diabetes mellitus and non-insulin-dependent type 2 diabetes mellitus. Students filled out standardized evaluations at the end of the session to assess receptiveness to this type of learning; opinions on the utility, information, and ease of use; and perceived risks of using the on-line simulator to understand diabetes. All students were receptive to this simulator-based educational approach. The majority found AIDA on-line useful (17/21 [81%]), educational (21/21 [100%]), worthy of wider distribution (20/21 [95%]), and would recommend the program to others with diabetes or wanting to learn about diabetes (18/21 [86%]). A minority (2/21 [9.5%]) found the program 'risky' regarding the information given to the students. Positive comments included the ability to visualize concepts being taught in earlier lectures, and recognized the rigors required to manage diabetes. Fewer negative comments reflected frustration with the web-based user interface, the course materials, or difficulty in achieving good simulated glycemic control. The study authors concluded that: "Teaching pathophysiology of diabetes and pharmacology of insulin to middle school students is enhanced with the AIDA on-line diabetes simulator. Future versions of this program, and development of similar programs, could be useful in teaching adolescents who have diabetes, and might help stimulate interested students to learn more about the care of people with diabetes". [22]

Randomised controlled trial (RCT)

The AIDA diabetes simulator has been tested out in a pilot randomised controlled trial (RCT). The protocol used for the RCT was described a priori in the medical / diabetes literature. [23] The study sought to assess whether diabetes educational teaching sessions using the AIDA simulator led to better outcomes than similar diabetes educational teaching sessions without a computer. The study was run at the Ospedale di Marino, near Rome, in Italy by an independent diabetologist / endocrinologist – unconnected with the simulator's development. Twenty-four volunteers (12 male and 12 female) with type 1 diabetes of more than 6-years duration, aged 19–48 years, who gave written informed consent, were randomly assigned to one of two study groups, each receiving different teaching interventions. Group A was exposed to the AIDA diabetes simulator, while Group B (the control group) received conventional lessons with slides and transparencies. Six lessons were held for each group (one per week). At the beginning and end of the study all subjects had their glycated hemoglobin (HbA1c) measured. The subjects also carefully documented the incidence of any symptomatic hypoglycaemic episodes ('hypos'), whether mild (sweating, dizziness), moderate (nausea, vomiting), or severe (requiring assistance).

The results seem encouraging. HbA1c levels in Group A dropped significantly from 7.2% to 6.4% after lessons with the diabetes simulator (p = 0.01). No significant changes in HbA1c were observed in the control group (Group B) between baseline (7.1%) and the end of the control lessons (7.0%). The number of 'hypos' decreased significantly from 31 to 14 in Group A (p = 0.03) after AIDA lessons, but did not change significantly in Group B from baseline (n = 20) to after the control lessons (n = 22). Full details of the study and the results can be found in the medical / diabetes literature. The study authors concluded that "larger trials involving more patients in more centres are clearly needed, but this proof-of-concept (pilot) study does demonstrate the feasibility of using a prospective randomised controlled trial approach for the evaluation of educational diabetes simulation software such as AIDA". [24]

Diabetes / Insulin Tutorial

There is an abundance of textual / static graphical information about insulin and diabetes on the web. However an AIDA-based Diabetes / Insulin Tutorial has been developed. The tutorial is unusual in that — in addition to offering textual / static graphical information about insulin and diabetes — it is also integrated with the AIDA on-line web-based diabetes simulator. In this way, visitors can not only read about insulin dosage adjustment in diabetes, but also interactively simulate examples of what they are learning about. The tutorial is currently arranged in four sections: (1) Insulin-dosage adjustment, (2) Choosing the insulin dose, (3) Timing of meals & diet planning, and (4) Glucose & the kidney. [25]

Guidelines for health-carers planning to teach with AIDA

An independent diabetologist / endocrinologist — unconnected with AIDA's development — has teamed up with one of the AIDA developers to highlight ways in which health-carer professionals may improve the outcome of lessons that make use of the simulator. Among the most important points highlighted seem to be the preparation of the teacher, consideration of how to impart preliminary information to help people understand the pathophysiology of diabetes, the optimum selection of topics to be covered, the arrangement of the lessons, how to involve each of the participants, and how to deal with questions. Other important issues include how to spot and deal with some of the difficulties that may be encountered by participants who apparently seem uninterested, obtaining feedback from the lessons, and practical ideas about how to lead a class. Guidelines for health-care professionals planning to teach with AIDA have been published in the diabetes literature. [26]

The same authors have also put together some recommended training requirements for health-carers planning to teach using the AIDA interactive educational diabetes simulator. The researchers have set out to answer possible questions from teachers using the program, highlight some minimum recommended training requirements for the software, suggest some "hints and tips" for teaching ideas, explain the importance of performing more studies / trials with the program, overview randomised controlled trial usage of the software, and highlight the importance of obtaining feedback from lesson participants. The recommendations seem to be straightforward and should help in formalising training with the program, as well as in the development of a network of teachers "accredited" to give lessons using the software. [27]

User reviews

Independent user reviews of the AIDA software can be found in the medical / diabetes / computing literature. [28] [29] [30] [31] [32] The AIDA diabetes simulator has been independently selected for inclusion in the United Kingdom National Health Service National Library for Health Diabetes Specialist Library list of Web resources.

Non-insulin dependent (type 2) diabetes mellitus

The current releases of the downloadable AIDA software, and AIDA on-line, do not incorporate functions to model endogenous insulin secretion — which takes place in people with non-insulin dependent diabetes mellitus type 2, and healthy subjects without diabetes. Nevertheless, a wide number of people with insulin-treated type 2 diabetes mellitus have reported finding the AIDA diabetes simulator of use for learning about balancing insulin and diet in diabetes. [33] This is because many of the principles of insulin dosage adjustment are remarkably similar in both type 1 and type 2 diabetes mellitus, and even without an endogenous insulin secretion model function, AIDA still can offer realistic simulations (from an educational perspective) for people with non-insulin dependent (type 2) diabetes mellitus. The AIDA developers have published a research paper in 2011 which includes reference to the incorporation of a dedicated function for pancreatic insulin secretion — to be added to a future release of the simulator. [34]

Further developments

Given the widespread usage of the AIDA diabetes simulation software, there has been considerable interest worldwide in updates to the program. Work has been reported in the scientific literature into the incorporation of lispro (Humalog)-like rapidly acting insulin analogues, and the glargine (Lantus) very long-acting insulin analogue, into the freeware diabetes simulator. Further information can be found in the medical / scientific literature. [35] [36] [37] A beta release of AIDA [v4.5c (beta)] incorporating lispro, regular, NPH and glargine insulins is available for download from the AIDA website. AIDA v4.5c (beta) is still undergoing testing / further development but has been available without charge from the AIDA website since 2012.

Research use

Separate from its utility as an educational, self-learning, or teaching tool for people with diabetes and their relatives / carers, students and health-care professionals — various research groups around the world have found the freeware AIDA diabetes simulator of use as a way of generating large quantities of realistic blood glucose data for developing and testing out their own diabetes computing prototypes (e.g. for training artificial neural networks, or other decision support research prototypes). Various published examples of this research approach can be found in the scientific literature. [38] [39]

Appendix: Download surveys / evaluations

The AIDA developers have undertaken a range of surveys and evaluations of usage of the AIDA diabetes simulator — to better understand who is downloading the program, and why.

One initial study analysed data from 1,360 downloads of the AIDA software. The intended goals of the survey were: (i) to establish the feasibility of using the Internet for auditing and surveying diabetes software users; (ii) to identify the proportion of people with diabetes and their relatives who are actually making use of the program; and (iii) to establish certain technical details about downloaders' computer setups to facilitate the distribution of upgrades to the software. 1,360 responses were received over an 8-month period (from November 1999 to July 2000). During the corresponding period 3,821 actual downloads of the software were independently logged at the Website — giving a response rate to this survey of 35.6%. Responses were received from participants in 67 countries — although over half of these (n=730, 54%) originated from the US and UK. 762 responses (56%) were received from people with diabetes and 184 (13.5%) from relatives of patients, with lesser numbers from doctors, students, diabetes educators, nurses, pharmacists, and other end users. Useful technical information about computers and operating systems being used were also obtained. The initial study established the feasibility of using the Internet to survey, at no real cost, a large number of medical software downloaders / users. In addition it yielded interesting data in terms of who are the main downloaders of the AIDA program, and has also provided technical (computer) information which aided the release of a freeware upgrade to the software. [40]

A second study audited 2,437 separate downloads of the AIDA program. The Internet-based survey methodology was confirmed to be robust and reliable. Over a 7.5-month period (from mid-July 2000 to early March 2001) 2,437 responses were received. During the corresponding period 4,100 actual downloads of the software were independently logged via the same route at the AIDA Website — giving a response rate to this audit of 59.4%. Responses were received from participants in 61 countries — although over half of these (n 5 1,533; 62.9%) originated from the United States and United Kingdom. Of these responses 1,361 (55.8%) were received from people with diabetes and 303 (12.4%) from relatives of patients, with fewer responses from doctors, diabetes educators, students, nurses, pharmacists, and other end users. This study has confirmed the feasibility of using the Internet to survey, at no real cost, a large number of medical software downloaders / users. In addition, it yielded up-to-date and interesting data about who are the main downloaders of the AIDA program. [41]

A third study surveyed downloaders of a more recent release of the program (AIDA v4.3a). Over a 1-year period (from March 2001 to February 2002) in total 3,864 responses were received. During the corresponding period some 8,578 actual downloads of the software were independently logged via the same route at the AIDA Website, giving a response rate for this survey of 45%. Responses were received from participants in 66 countries — over half of these (n=2,137; 55.3%) were from the United States and the United Kingdom. There were 2,318 responses (60.0%) received from people with diabetes and 443 (11.5%) from relatives of patients, with fewer responses from doctors, students, diabetes educators, nurses, pharmacists, and other end users. The authors concluded that the study highlighted "considerable interest amongst patients and their relatives to learn more about balancing insulin and diet in diabetes, as well as possibly to get more involved in self-management of insulin dosages. More computer applications that can cater for this interest in diabetes patient self-care need to be developed and made available. The Internet provides an ideal medium for the distribution of such educational tools". [42]

Related Research Articles

<span class="mw-page-title-main">Insulin pump</span> Medical device to administer insulin

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy. The device configuration may vary depending on design. A traditional pump includes:

Intensive insulin therapy or flexible insulin therapy is a therapeutic regimen for diabetes mellitus treatment. This newer approach contrasts with conventional insulin therapy. Rather than minimize the number of insulin injections per day, the intensive approach favors flexible meal times with variable carbohydrate as well as flexible physical activities. The trade-off is the increase from 2 or 3 injections per day to 4 or more injections per day, which was considered "intensive" relative to the older approach. In North America in 2004, many endocrinologists prefer the term "flexible insulin therapy" (FIT) to "intensive therapy" and use it to refer to any method of replacing insulin that attempts to mimic the pattern of small continuous basal insulin secretion of a working pancreas combined with larger insulin secretions at mealtimes. The semantic distinction reflects changing treatment.

<span class="mw-page-title-main">Blood glucose monitoring</span> Use of a glucose monitor for testing the concentration of glucose in the blood

Blood glucose monitoring is the use of a glucose meter for testing the concentration of glucose in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed by piercing the skin to draw blood, then applying the blood to a chemically active disposable 'test-strip'. The other main option is continuous glucose monitoring (CGM). Different manufacturers use different technology, but most systems measure an electrical characteristic and use this to determine the glucose level in the blood. Skin-prick methods measure capillary blood glucose, whereas CGM correlates interstitial fluid glucose level to blood glucose level. Measurements may occur after fasting or at random nonfasting intervals, each of which informs diagnosis or monitoring in different ways.

<span class="mw-page-title-main">Glucose tolerance test</span> Medical test of how quickly glucose is cleared from the blood

The glucose tolerance test is a medical test in which glucose is given and blood samples taken afterward to determine how quickly it is cleared from the blood. The test is usually used to test for diabetes, insulin resistance, impaired beta cell function, and sometimes reactive hypoglycemia and acromegaly, or rarer disorders of carbohydrate metabolism. In the most commonly performed version of the test, an oral glucose tolerance test (OGTT), a standard dose of glucose is ingested by mouth and blood levels are checked two hours later. Many variations of the GTT have been devised over the years for various purposes, with different standard doses of glucose, different routes of administration, different intervals and durations of sampling, and various substances measured in addition to blood glucose.

<span class="mw-page-title-main">Hyperglycemia</span> Too much blood sugar, usually because of diabetes

Hyperglycemia or Hyperglycaemia is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/L (200 mg/dL), but symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/L (~250–300 mg/dL). A subject with a consistent fasting blood glucose range between ~5.6 and ~7 mmol/L is considered slightly hyperglycemic, and above 7 mmol/L is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dL) can produce noticeable organ damage over time.

<span class="mw-page-title-main">Type 2 diabetes</span> Form of diabetes mellitus

Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. Symptoms may also include increased hunger, having a sensation of pins and needles, and sores (wounds) that do not heal. Often symptoms come on slowly. Long-term complications from high blood sugar include heart disease, stroke, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.

Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists, and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors.

<span class="mw-page-title-main">Gestational diabetes</span> Medical condition

Gestational diabetes is a condition in which a person without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes generally results in few symptoms; however, it increases the risk of pre-eclampsia, depression, and of needing a Caesarean section. Babies born to individuals with poorly treated gestational diabetes are at increased risk of macrosomia, of having hypoglycemia after birth, and of jaundice. If untreated, diabetes can also result in stillbirth. Long term, children are at higher risk of being overweight and of developing type 2 diabetes.

Glycated hemoglobin, glycohemoglobin, glycosylated hemoglobin is a form of hemoglobin (Hb) that is chemically linked to a sugar. Several types of glycated hemoglobin measures exist, of which HbA1c, or simply A1c, is a standard single test. Most monosaccharides, including glucose, galactose, and fructose, spontaneously bond with hemoglobin when present in the bloodstream. However, glucose is only 21% as likely to do so as galactose and 13% as likely to do so as fructose, which may explain why glucose is used as the primary metabolic fuel in humans.

<span class="mw-page-title-main">Diabetes UK</span> British charity

Diabetes UK is a British-based patient, healthcare professional and research charity that has been described as "one of the foremost diabetes charities in the UK". The charity campaigns for improvements in the care and treatment of people with diabetes.

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

A diabetic diet is a diet that is used by people with diabetes mellitus or high blood sugar to minimize symptoms and dangerous complications of long-term elevations in blood sugar.

<span class="mw-page-title-main">Voglibose</span> Alpha-glucosidase inhibitor

Voglibose is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Vogilbose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.

<span class="mw-page-title-main">Prediabetes</span> Predisease state of hyperglycemia with high risk for diabetes

Prediabetes is a component of metabolic syndrome and is characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes mellitus. It usually does not cause symptoms but people with prediabetes often have obesity, dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. It is also associated with increased risk for cardiovascular disease (CVD). Prediabetes is more accurately considered an early stage of diabetes as health complications associated with type 2 diabetes often occur before the diagnosis of diabetes.

The dawn phenomenon, sometimes called the dawn effect, is an observed increase in blood sugar (glucose) levels that takes place in the early-morning, often between 2 a.m. and 8 a.m. First described by Schmidt in 1981 as an increase of blood glucose or insulin demand occurring at dawn, this naturally occurring phenomenon is frequently seen among the general population and is clinically relevant for patients with diabetes as it can affect their medical management. In contrast to Chronic Somogyi rebound, the dawn phenomenon is not associated with nocturnal hypoglycemia.

<span class="mw-page-title-main">Minimed Paradigm</span> Insulin pumps

MiniMed Paradigm is a series of insulin pumps manufactured by Medtronic for patients with diabetes mellitus. The pump operates with a single AAA battery and uses a piston-plunger pump to infuse a programmed amount of insulin into the patient through a length of tubing. The Paradigm uses a one-way wireless radio frequency link to receive blood sugar measurements from select glucose meters. The Paradigm RT series adds the ability to receive data from a mated continuous blood-glucose monitor. Although the pump can use these measurements to assist in calculating a dose of insulin, no actual change in insulin delivery occurs without manual user-intervention.

<span class="mw-page-title-main">1,5-Anhydroglucitol</span> Chemical compound

1,5-Anhydroglucitol, also known as 1,5-AG, is a naturally occurring monosaccharide found in nearly all foods. Blood concentrations of 1,5-anhydroglucitol decrease during times of hyperglycemia above 180 mg/dL, and return to normal levels after approximately 2 weeks in the absence of hyperglycemia. As a result, it can be used for people with either type-1 or type-2 diabetes mellitus to identify glycemic variability or a history of high blood glucose even if current glycemic measurements such as hemoglobin A1c (HbA1c) and blood glucose monitoring have near normal values. Despite this possible use and its approval by the FDA, 1,5-AG tests are rarely ordered. There is some data suggesting that 1,5-AG values are useful to fill the gap and offer complementary information to HbA1c and fructosamine tests.

Chromium is claimed to be an essential element involved in the regulation of blood glucose levels within the body. More recent reviews have questioned this, however.

<span class="mw-page-title-main">Diabetes</span> Group of endocrine diseases characterized by high blood sugar levels

Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Diabetes accounts for approximately 4.2 million deaths every year, with an estimated 1.5 million caused by either untreated or poorly treated diabetes.

Robert A. Vigersky is an American endocrinologist, Professor of Medicine at the Uniformed Services University of the Health Sciences, and pioneering military healthcare professional. His career has focused on diabetes care, research, and advocacy, publishing 148 papers and 118 abstracts in the fields of reproductive endocrinology and diabetes. Vigersky is a retired colonel in the U.S. Army Medical Corps, past president of the Endocrine Society, and recipient of the General Maxwell R. Thurman Award. He served in Iraq, Korea and Germany and is the recipient of military awards including the U.S. Army's Legion of Merit in 2009.

References

  1. ↑ Lehmann, E. D. (1999). "Experience with the Internet release of AIDA v4 — an interactive educational diabetes simulator" (PDF). Diabetes Technol Ther. 1 (1): 41–54. doi:10.1089/152091599317567. PMID   11475304.
  2. ↑ "A physiological model of glucose-insulin interaction" (PDF). In: IEEE EMBS Proceedings, 13th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 13 (5): 2274–2275. 1991.
  3. ↑ Lehmann ED (June 1996). "Diabetes moves onto the Internet". Lancet. 347 (9014): 1542. doi: 10.1016/s0140-6736(96)90684-4 . S2CID   54231692.
  4. ↑ Lehmann ED, Deutsch T, Carson ER, Sonksen PH (April 1994). "Combining rule-based reasoning and mathematical modelling in diabetes care". Artif Intell Med. 6 (2): 137–160. doi:10.1016/0933-3657(94)90042-6. PMID   8049754.
  5. ↑ Lehmann ED, Deutsch T, Carson ER, Sonksen PH (Jan 1994). "AIDA: an interactive diabetes advisor". Comput Methods Programs Biomed. 41 (3–4): 183–203. doi:10.1016/0169-2607(94)90054-x. PMID   8187465.
  6. ↑ Lehmann, E.D.; Deutsch, T. (1996). "Computer assisted diabetes care: a 6 year retrospective" (PDF). Comput Methods Programs Biomed. 50 (3): 209–230. doi:10.1016/0169-2607(96)01751-8. PMID   8894381.
  7. ↑ Lehmann ED, Deutsch T, Broad D: AIDA: an educational simulator for insulin dosage and dietary adjustment in diabetes. British Diabetic Association, London, 1997.
  8. ↑ Lehmann, Eldon D. (2004). "British Diabetic Association review of the AIDA v4 diabetes software simulator program" (PDF). Diabetes Technol Ther. 6 (1): 87–96. CiteSeerX   10.1.1.608.1325 . doi:10.1089/152091504322783477. PMID   15000776.
  9. ↑ Lehmann ED, Deutsch T (May 1993). "AIDA2: a Mk. II automated insulin dosage advisor". J Biomed Eng. 15 (3): 201–11. doi:10.1016/0141-5425(93)90116-g. PMID   8320979.
  10. ↑ Lehmann ED, Deutsch T (May 1992). "A physiological model of glucose-insulin interaction in type 1 diabetes mellitus". J Biomed Eng. 14 (3): 235–42. doi:10.1016/0141-5425(92)90058-s. PMID   1588781.
  11. ↑ Lehmann ED, Hermanyi I, Deutsch T (May 1994). "Retrospective validation of a physiological model of glucose-insulin interaction in type 1 diabetes mellitus". Med Eng Phys. 16 (3): 193–202. doi:10.1016/1350-4533(94)90038-8. PMID   8061905.
  12. ↑ Lehmann, E.D; Deutsch, T. (1998). "Compartmental models for glycaemic prediction and decision-support in clinical diabetes care: promise and reality" (PDF). Comput Methods Programs Biomed. 56 (2): 193–204. doi:10.1016/s0169-2607(98)00025-x. PMID   9700433.
  13. ↑ Lehmann, Eldon D.; Dewolf, Dennis K.; Novotny, Christopher A.; Reed, Karen; Gotwals, Robert R. (2014). "Dynamic interactive educational diabetes simulations using the world wide web: an experience of more than 15 years with AIDA online" (PDF). International Journal of Endocrinology. 2014 (Article ID 692893): 25pp. doi: 10.1155/2014/692893 . PMC   3913388 . PMID   24511312.
  14. ↑ Lehmann ED (1997). "Interactive educational simulators in diabetes care". Med Inform (Lond). 22 (1): 47–76. doi:10.3109/14639239709089834. PMID   9183780.
  15. ↑ Lehmann, E.D (1998). "Preliminary experience with the Internet release of AIDA — an interactive educational diabetes simulator" (PDF). Comput Methods Programs Biomed. 56 (2): 109–132. CiteSeerX   10.1.1.510.7114 . doi:10.1016/s0169-2607(98)00019-4. PMID   9700427.
  16. ↑ "The freeware AIDA interactive educational diabetes simulator — www.2aida.org — (2) Simulating glycosylated haemoglobin (HbA1c) levels in AIDA v4.3" (PDF). Medical Science Monitor. 7 (3): 516–525. 2001.
  17. ↑ Lehmann, E. D. (2001). "Simulating glycosylated hemoglobin (HbA1c) levels in diabetes using an interactive educational virtual diabetes patient simulator" (PDF). Diabetes Technol Ther. 3 (3): 517–524. doi:10.1089/15209150152607268. PMID   11762526.
  18. ↑ Lehmann, Eldon D. (2002). "Further user comments regarding usage of an interactive educational diabetes simulator (AIDA)" (PDF). Diabetes Technol Ther. 4 (1): 121–135. CiteSeerX   10.1.1.610.4525 . doi:10.1089/15209150252924175. PMID   12017414.
  19. ↑ Tatti P; et al. (2001). "Utility of the AIDA diabetes simulator as an interactive educational teaching tool for general practitioners (primary care physicians)" (PDF). Diabetes Technol Ther. 3 (1): 133–140. doi:10.1089/152091501750220118. PMID   11469705.
  20. ↑ Tatti P; et al. (2001). "Use of the AIDA diabetes simulation software — www.2aida.org — as an interactive educational tool for teaching student nurses" (PDF). Diabetes Technol Ther. 3 (4): 655–664. CiteSeerX   10.1.1.618.2230 . doi:10.1089/15209150152811315. PMID   11911181.
  21. ↑ Narayan KMV; et al. (2003). "Lifetime risk for diabetes mellitus in the United States". JAMA. 290 (14): 1884–1890. doi:10.1001/jama.290.14.1884. PMID   14532317.
  22. ↑ Palacio A; et al. (January 2007). "Teaching diabetes to middle-school students with the www.2aida.net AIDA online diabetes software simulator" (PDF). Journal of Diabetes Science and Technology. 1 (1): 106–115. doi:10.1177/193229680700100116. PMC   2769599 . PMID   19888387.
  23. ↑ Tatti P; et al. (2001). "A randomised-controlled clinical trial methodology for evaluating the teaching utility of interactive educational diabetes simulators" (PDF). Diabetes Nutrition & Metabolism. 14 (1): 1–17. PMID   11345161.
  24. ↑ Tatti P; et al. (2003). "A prospective randomised-controlled pilot study for evaluating the teaching utility of interactive educational diabetes simulators" (PDF). Diabetes Nutrition & Metabolism. 16 (1): 7–23. PMID   12848301.
  25. ↑ Reed K; et al. (2006). "Interactive Educational Diabetes/Insulin Tutorial at www.2aida.info" (PDF). Diabetes Technol Ther. 8 (1): 126–137. doi:10.1089/dia.2006.8.126. PMID   16472060.
  26. ↑ Tatti P; et al. (2002). "Using the AIDA — www.2aida.org — diabetes simulator. Part 1: Recommended guidelines for health-carers planning to teach with the software" (PDF). Diabetes Technol Ther. 4 (3): 401–414. doi:10.1089/152091502760098546. PMID   12165178.
  27. ↑ Lehmann, Eldon D.; Tatti, Patrizio (2002). "Using the AIDA — www.2aida.org — diabetes simulator. Part 2: Recommended training requirements for health-carers planning to teach with the software" (PDF). Diabetes Technol Ther. 4 (5): 717–732. doi:10.1089/152091502320798349. PMID   12450452.
  28. ↑ Wilson DM (1999). "Diabetes simulators: ready for prime time?" (PDF). Diabetes Technol Ther. 1 (1): 55–6. doi:10.1089/152091599317576. PMID   11475305.
  29. ↑ Kerr, D.; Cavan, D. (1999). "Website Review. The Virtual Diabetic Patient: AIDA on-line". Diabetes Metab Res Rev. 15 (3): 226. doi:10.1002/(sici)1520-7560(199905/06)15:3<226::aid-dmrr33>3.3.co;2-r. PMID   10441045.
  30. ↑ Chausmer AB (September–October 2002). "Diabetes management tools for patients and physicians". Medical Software Reviews. 11. CRI Health Care Publications: 1–16.
  31. ↑ Parslow GR (2004). "Websites of Note". Biochemistry and Molecular Biology Education. 32 (3): 207–9. doi: 10.1002/bmb.2004.494032030343 . PMID   21706726. S2CID   2992098.
  32. ↑ Tatti P (2006). "AIDA: Un nuovo strumento educativo per il paziente con diabete". In: 1st National Congress of Progetto Diabete, Genova, Italy, p.31 (in Italian).
  33. ↑ Lehmann, Eldon D.; Chatu, Sukhdev S.; Hashmy, S. Sabina H. (2006). "Retrospective pilot feedback survey of 200 users of the AIDA version 4 educational diabetes program. 1. Quantitative survey data" (PDF). Diabetes Technol Ther. 8 (3): 419–432. doi:10.1089/dia.2006.8.419. PMID   16800766.
  34. ↑ Lehmann, Eldon D.; Tarín, Cristina; Bondia, Jorge; Teufel, Edgar; Deutsch, Tibor (2011). "Development of AIDA v4.3b diabetes simulator: technical upgrade to support incorporation of lispro, aspart and glargine insulin analogues" (PDF). Journal of Electrical and Computer Engineering. 2011: 17pp. doi: 10.1155/2011/427196 .
  35. ↑ Lehmann, E. D.; Tarín, C.; Bondia, J.; Teufel, E.; Deutsch, T. (2007). "Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 1. A prospective collaborative development plan" (PDF). Journal of Diabetes Science and Technology. 1 (3): 423–435. doi:10.1177/193229680700100317. PMC   2769582 . PMID   19885100.
  36. ↑ Lehmann, Eldon D.; Tarín, Cristina; Bondia, Jorge; Teufel, Edgar; Deutsch, Tibor (2007). "Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 2. Preliminary bench testing" (PDF). Journal of Diabetes Science and Technology. 1 (5): 780–793. doi:10.1177/193229680700100525. PMC   2769650 . PMID   19885148.
  37. ↑ Lehmann, Eldon D.; Tarín, Cristina; Bondia, Jorge; Teufel, Edgar; Deutsch, Tibor (2009). "Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 3. Early plasma insulin determinations" (PDF). Journal of Diabetes Science and Technology. 3 (1): 190–201. doi:10.1177/193229680900300123. PMC   2769853 . PMID   20046665. Archived from the original (PDF) on 2012-03-21. Retrieved 2011-06-12.
  38. ↑ Lehmann, Eldon D. (2003). "Research use of the AIDA www.2aida.org diabetes software simulation program: a review — Part 1. Decision support testing and neural network training" (PDF). Diabetes Technol Ther. 5 (3): 425–438. doi:10.1089/152091503765691938. PMID   12828827.
  39. ↑ Lehmann, Eldon D. (2003). "Research use of the AIDA www.2aida.org diabetes software simulation program: a review — Part 2. Generating simulated blood glucose data for prototype validation" (PDF). Diabetes Technol Ther. 5 (4): 641–651. doi:10.1089/152091503322250668. PMID   14511419.
  40. ↑ "The freeware AIDA interactive educational diabetes simulator - www.2aida.org - (1) A download survey for AIDA v4.0" (PDF). Med Sci Monit. 7 (3): 504–515. 2001.
  41. ↑ Lehmann, Eldon D. (2002). "Who is downloading the freeware AIDA v4.3 interactive educational diabetes simulator? An audit of 2,437 downloads" (PDF). Diabetes Technol Ther. 4 (4): 467–477. CiteSeerX   10.1.1.424.3951 . doi:10.1089/152091502760306553. PMID   12396741.
  42. ↑ Lehmann, Eldon D. (2003). "Who is downloading the free AIDA v4.3a interactive educational diabetes computer software? A 1-year survey of 3,864 downloads" (PDF). Diabetes Technol Ther. 5 (5): 879–890. doi:10.1089/152091503322527148. PMID   14633359.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.